AAD: Continuous Improvements Seen Through 68 Weeks for Deuruxolitinib in Alopecia
TUESDAY, March 19, 2024 -- For adults with alopecia areata, continuous improvements are seen through 68 weeks with deuruxolitinib, according to a study presented at the annual meeting of the American Academy of Dermatology, held from March 8 to 12... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 19, 2024 Category: Pharmaceuticals Source Type: news
AAD: Hair Regrowth Continues to Improve at 76 Weeks With Baricitinib for Severe Alopecia
MONDAY, March 18, 2024 -- Continuous treatment with baricitinib in patients with severe alopecia areata demonstrates improvement in hair regrowth outcomes through 76 weeks of follow-up, according to a study presented at the annual meeting of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 18, 2024 Category: Pharmaceuticals Source Type: news
One-a-Day Pill for Alopecia Recommended for NHS Use One-a-Day Pill for Alopecia Recommended for NHS Use
NICE said there is unequal treatment for people with severe alopecia areata across England and Wales and its approval of ritlecitinib could benefit up to 14,000 people.Medscape News UK (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - February 22, 2024 Category: Dermatology Tags: Dermatology Source Type: news
Study Estimates Post-COVID Risk for Alopecia Areata Study Estimates Post-COVID Risk for Alopecia Areata
The incidence of alopecia areata in patients with COVID-19 was significantly higher than that in the uninfected controls, in a large Korean cohort study.MDedge News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - January 15, 2024 Category: Allergy & Immunology Tags: Dermatology Source Type: news
Alopecia on the Rise After COVID, Study Suggests
(MedPage Today) -- The incidence of alopecia areata significantly increased after COVID-19, a nationwide study involving more than half a million South Koreans found.
In a propensity score-matched analysis, incidence of the autoimmune form of... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - January 10, 2024 Category: Dermatology Source Type: news
Sun Pharma subsidiary partners with Aclaris Therapeutics for licensing agreement
As per the pact, Aclaris grants Sun Pharma exclusive rights to specific patents for using deuruxolitinib, Sun Pharma's JAK inhibitor, or other isotopic forms of ruxolitinib, specifically for treating alopecia areata (AA) or androgenetic alopecia (AGA). (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 6, 2023 Category: Pharmaceuticals Source Type: news
A commonly used arthritis medicine can cure baldness, shows a study
A recent study published in Indian Dermatology has found that tofacitinib, a drug commonly used for rheumatoid arthritis, has shown promising results in treating alopecia areata. The study revealed that 94.1% of the patients showed a complete or near-complete response to the medication. Additionally, 23.5% of the patients achieved complete hair growth within eight months of treatment. (Source: The Economic Times)
Source: The Economic Times - November 21, 2023 Category: Consumer Health News Source Type: news
NHS watchdog considers anti hair loss pill to combat alopecia, which affects celebrities such as Jada Pinkett Smith, offering hope to 100,000 people
The drug, ritlecitinib, can trigger hair regrowth within six months. It is used to treat alopecia areata, a condition which affects 100,000 Britons and celebrities such as Jada Pinkett Smith. (Source: the Mail online | Health)
Source: the Mail online | Health - September 23, 2023 Category: Consumer Health News Source Type: news
Most Adults With Alopecia Areata Untreated 1 Year After Dx Most Adults With Alopecia Areata Untreated 1 Year After Dx
In the study, two-thirds of newly diagnosed patients had received at least one treatment within the first year of diagnosis.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - September 21, 2023 Category: Dermatology Tags: Dermatology News Source Type: news
Study Looks at Treatment Patterns for Alopecia Areata
WEDNESDAY, Sept. 20, 2023 -- For patients with alopecia areata (AA), corticosteroids are the most commonly used treatment, and by one year, 71.8 percent are receiving no treatment, according to a study published online Sept. 20 in JAMA... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 20, 2023 Category: Pharmaceuticals Source Type: news
European Commission Approves Ritlecitinib for Severe AA European Commission Approves Ritlecitinib for Severe AA
This makes ritlecitinib the first medicine authorized by the EC to treat individuals with severe alopecia areata as young as 12 years of age.MDedge News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - September 19, 2023 Category: Dermatology Tags: Dermatology News Alert Source Type: news
Utilization of Topical Ruxolitinib in Dermatology Utilization of Topical Ruxolitinib in Dermatology
This review summarizes the use of topical ruxolitinib, a JAK inhibitor, in various dermatological conditions including vitiligo, alopecia areata, atopic dermatitis, psoriasis, and more.Skin Therapy Letter (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 4, 2023 Category: Allergy & Immunology Tags: Dermatology Journal Article Source Type: news
A New Treatment Option for a Form of Sudden Hair Loss
THURSDAY, Aug. 17, 2023 -- A new type of medication, JAK inhibitors, can effectively treat moderate to severe alopecia areata, a hair loss condition that has been historically hard to treat.
A study of its effectiveness, by Dr. Brett King and Dr.... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 17, 2023 Category: General Medicine Source Type: news
Experiencing workplace bullying in patients with alopecia areata: a cross-sectional survey study - Li SJ, Reyes-Hadsall S, Drake L, Huang K, Mostaghimi A.
INTRODUCTION: Alopecia areata (AA) is an immune-mediated hair loss condition with substantial psychosocial impact. The impact of AA on social interactions at work has not been established. METHODS: We administered the Negative Acts Questionnaire-Re... (Source: SafetyLit)
Source: SafetyLit - August 15, 2023 Category: International Medicine & Public Health Tags: Occupational Issues Source Type: news
Evolving Story of JAK Inhibitors for Treating Alopecia Areata Evolving Story of JAK Inhibitors for Treating Alopecia Areata
Review the introduction of Janus kinase inhibitors and their application as the first-line therapeutic option for severe alopecia areata. What might be the future role of JAK inhibitors in this area?Skin Therapy Letter (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 3, 2023 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news
